Oditrasertib (DNL-788, SAR 443820) is a first-in-class, selective, orally bioavailable, brain penetrant inhibitor of Receptor-interacting serine/threonine protein kinase 1 (RIPK1). It can be used in research of myotrophic lateral sclerosis and multiple sclerosis.

CVN293 is a potent, selective, and brain permeable small-molecule inhibitor of potassium (K+) ion channel KCNK13 with an IC50s of 49 nM and 28 nM for hKCNK13 and mKCNK13, respectively. It also inhibits NOD-like receptor protein 3 (NLRP3) inflammasome-mediated IL-1ß production in LPS-stimulated primary neonatal murine microglia with an IC50 of 24 nM and has […]

CVN293 is a potent, selective, and brain permeable small-molecule inhibitor of potassium (K+) ion channel KCNK13 with an IC50s of 49 nM and 28 nM for hKCNK13 and mKCNK13, respectively. It also inhibits NOD-like receptor protein 3 (NLRP3) inflammasome-mediated IL-1ß production in LPS-stimulated primary neonatal murine microglia with an IC50 of 24 nM and has […]

Oditrasertib (DNL-788, SAR 443820) is a first-in-class, selective, orally bioavailable, brain penetrant inhibitor of Receptor-interacting serine/threonine protein kinase 1 (RIPK1). It can be used in research of myotrophic lateral sclerosis and multiple sclerosis.

Oditrasertib (DNL-788, SAR 443820) is a first-in-class, selective, orally bioavailable, brain penetrant inhibitor of Receptor-interacting serine/threonine protein kinase 1 (RIPK1). It can be used in research of myotrophic lateral sclerosis and multiple sclerosis.

Oditrasertib (DNL-788, SAR 443820) is a first-in-class, selective, orally bioavailable, brain penetrant inhibitor of Receptor-interacting serine/threonine protein kinase 1 (RIPK1). It can be used in research of myotrophic lateral sclerosis and multiple sclerosis.

FIDAS-5 is a potent and orally active inhibitor of methionine S-adenosyltransferase 2A (MAT2A) with an IC50 value of 2.1 μM, respectively. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 also demonstrates anticancer activity.

FIDAS-5 is a potent and orally active inhibitor of methionine S-adenosyltransferase 2A (MAT2A) with an IC50 value of 2.1 μM, respectively. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 also demonstrates anticancer activity.

FIDAS-5 is a potent and orally active inhibitor of methionine S-adenosyltransferase 2A (MAT2A) with an IC50 value of 2.1 μM, respectively. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 also demonstrates anticancer activity.

PK 11195 (RP 52028) is a translocator protein (TSPO) ligand, a potent and selective antagonist of peripheral benzodiazepine receptorwith high affinity Ki of 3.1 nM in cerebellum and 4.1 nM in spinal cord. It is also an antagonist of human constitutive androstane receptor (hCAR), and human pregnane X receptor (PXR). It displaces [3H] RO5-4864 from […]